[1]
Chong V, Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (London, England). 2016 Nov; [PubMed PMID: 27612184]
[2]
Chen Y,Han F, Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. Therapeutics and clinical risk management. 2012; [PubMed PMID: 22911433]
[3]
Hicklin DJ,Ellis LM, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Feb 10; [PubMed PMID: 15585754]
[4]
Krispel C,Rodrigues M,Xin X,Sodhi A, Ranibizumab in diabetic macular edema. World journal of diabetes. 2013 Dec 15; [PubMed PMID: 24379922]
[5]
Hsu JY,Wakelee HA, Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2009; [PubMed PMID: 19754219]
[6]
Lin RC,Rosenfeld PJ, Antiangiogenic therapy in neovascular age-related macular degeneration. International ophthalmology clinics. 2007 Winter; [PubMed PMID: 17237677]
[7]
Alon T,Hemo I,Itin A,Pe'er J,Stone J,Keshet E, Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature medicine. 1995 Oct; [PubMed PMID: 7489357]
[8]
Kim LA,D'Amore PA, A brief history of anti-VEGF for the treatment of ocular angiogenesis. The American journal of pathology. 2012 Aug; [PubMed PMID: 22749677]
[9]
Martin DF,Maguire MG,Ying GS,Grunwald JE,Fine SL,Jaffe GJ, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England journal of medicine. 2011 May 19; [PubMed PMID: 21526923]
[10]
Joachim SC,Renner M,Reinhard J,Theiss C,May C,Lohmann S,Reinehr S,Stute G,Faissner A,Marcus K,Dick HB, Protective effects on the retina after ranibizumab treatment in an ischemia model. PloS one. 2017; [PubMed PMID: 28800629]
[11]
Nguyen QD,Brown DM,Marcus DM,Boyer DS,Patel S,Feiner L,Gibson A,Sy J,Rundle AC,Hopkins JJ,Rubio RG,Ehrlich JS, Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr; [PubMed PMID: 22330964]
[12]
Evoy KE,Abel SR, Ranibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema. The Annals of pharmacotherapy. 2013 Jun; [PubMed PMID: 23656749]
[13]
van Asten F,Michels CTJ,Hoyng CB,van der Wilt GJ,Klevering BJ,Rovers MM,Grutters JPC, The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. PloS one. 2018; [PubMed PMID: 29772018]
[14]
Mohamad NA,Ramachandran V,Ismail P,Mohd Isa H,Chan YM,Ngah NF,Md Bakri N,Ching SM,Hoo FK,Wan Sulaiman WA, Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia. International journal of ophthalmology. 2017; [PubMed PMID: 29259909]
[16]
Papadopoulos N,Martin J,Ruan Q,Rafique A,Rosconi MP,Shi E,Pyles EA,Yancopoulos GD,Stahl N,Wiegand SJ, Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012 Jun; [PubMed PMID: 22302382]
[17]
Dugel PU,Singh N,Francom S,Cantrell RA,Grzeschik SM,Fung AE, The Systemic Safety of Ranibizumab in Patients 85 Years and Older with Neovascular Age-Related Macular Degeneration. Ophthalmology. Retina. 2018 Jul; [PubMed PMID: 31047375]
[18]
Stewart MW, A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. Ophthalmology and therapy. 2017 Jun; [PubMed PMID: 28324452]
[19]
Bressler SB,Almukhtar T,Bhorade A,Bressler NM,Glassman AR,Huang SS,Jampol LM,Kim JE,Melia M, Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA ophthalmology. 2015 May; [PubMed PMID: 25719991]
[20]
Wang W,Zhang X, Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis. PloS one. 2014; [PubMed PMID: 25330364]
[21]
Kampougeris G,Spyropoulos D,Mitropoulou A, Intraocular Pressure rise after Anti-VEGF Treatment: Prevalence, Possible Mechanisms and Correlations. Journal of current glaucoma practice. 2013 Jan-Apr; [PubMed PMID: 26997776]
[22]
Falavarjani KG,Nguyen QD, Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (London, England). 2013 Jul; [PubMed PMID: 23722722]
[23]
Fintak DR,Shah GK,Blinder KJ,Regillo CD,Pollack J,Heier JS,Hollands H,Sharma S, Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina (Philadelphia, Pa.). 2008 Nov-Dec; [PubMed PMID: 18827737]
[24]
Karagiannis DA,Mitropoulos P,Ladas ID, Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2009; [PubMed PMID: 19390227]
[25]
Modarres M,Naseripour M,Falavarjani KG,Nikeghbali A,Hashemi M,Parvaresh MM, Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. Retina (Philadelphia, Pa.). 2009 Mar; [PubMed PMID: 19287288]
[26]
Lim LS,Cheung CMG,Mitchell P,Wong TY, Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned? American journal of ophthalmology. 2011 Sep; [PubMed PMID: 21855670]
[27]
Holz FG,Bandello F,Gillies M,Mitchell P,Osborne A,Sheidow T,Souied E,Figueroa MS, Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. The British journal of ophthalmology. 2013 Sep; [PubMed PMID: 23850682]
[28]
Xu L,Lu T,Tuomi L,Jumbe N,Lu J,Eppler S,Kuebler P,Damico-Beyer LA,Joshi A, Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Investigative ophthalmology [PubMed PMID: 23361508]
[29]
Manousaridis K,Talks J, Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease? The British journal of ophthalmology. 2012 Feb; [PubMed PMID: 22250209]
[30]
Merz PR,Röckel N,Ballikaya S,Auffarth GU,Schmack I, Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells. BMC ophthalmology. 2018 Dec 11; [PubMed PMID: 30537942]